Medivation Inc

Medivation — Q1 2016 Earnings Presentation

17 slides from Medivation's earnings presentation, May 6, 2016

  1. Slide 1: Financial and Corporate Update

    Financial and Corporate Update Exhibit 99.1

  2. Slide 2: Speakers

    Speakers David Hung, M.D. – Founder, President and CEO Marion McCourt – Chief Operating Officer Jennifer Jarrett – Chief Financial Officer Mohammad Hirmand, M.D. – Interim Chief Medical Officer

  3. Slide 3: Additional Information: Forward-Looking Statements

    Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, our anticipat

  4. Slide 4: David Hung, M.D. – Founder, President and CEO

    David Hung, M.D. Founder, President and CEO

  5. Slide 5: Marion McCourt – Chief Operating Officer

    Marion McCourt Chief Operating Officer

  6. Slide 6: Jennifer Jarrett – Chief Financial Officer

    Jennifer Jarrett Chief Financial Officer

  7. Slide 7: U.S. XTANDI Net Sales

    Year over year increase in U.S. XTANDI net sales of 37% was driven by an increase in underlying demand of 33% Sequential quarter decrease in U.S. XTANDI net sales in Q1 2016 was due to higher gross-to-net (due to reset of Medicare Part D “donut hole”) and a decrease in inventory at channel partners

  8. Slide 8: Ex-U.S. XTANDI Net Sales

    +80% increase y-o-y Ex-U.S. XTANDI Net Sales As recorded by Astellas Ex-US XTANDI net sales were approximately $240 million in Q1 2016, an increase of 80% compared to Q1 2015 The increase was primarily driven by growth in Germany, France and Japan Key Metrics & Comments

  9. Slide 9: Medivation Non-GAAP Revenue

    Medivation Non-GAAP Revenue Non-GAAP revenues typically lower in first quarter of calendar year due to: Reset of royalty rate on ex-U.S. net sales of XTANDI effective January 1st of each calendar year The seasonal effects that were detailed on the previous slide, notable a higher gross to net accrua

  10. Slide 10: Non-GAAP R&D Expenses

    Non-GAAP R&D Expenses Year over year increase in Non-GAAP R&D, primarily related to our talazoparib program which we acquired in October 2015 Modest 11% quarter over quarter growth and this sequential growth rate is expected to decline in subsequent quarters Key Metrics & Comments Acquired Talazopar

  11. Slide 11: Non-GAAP SG&A Expenses

    Non-GAAP SG&A Expenses First quarter Non-GAAP SG&A expenses were impacted by annually recurring collaboration expenses incurred by Astellas that are expensed to us almost entirely in the first quarter of the year Consistent with last year, we expect our Non-GAAP SG&A expense to decrease in subsequen

  12. Slide 12: Non-GAAP EPS

    Non-GAAP EPS First quarter EPS generally lower due to: Lower Non-GAAP revenues due to 1) reset of royalty rate on XTANDI ex-U.S. net sales and 2) higher gross to net and inventory changes related to US net sales of XTANDI Higher Non-GAAP S&GA expenses due to timing of certain collaboration expenses

  13. Slide 13: Reaffirming Full Year 2016 Non-GAAP Guidance

    Reaffirming Full Year 2016 Non-GAAP Guidance All amounts in $ millions except for Tax Rate and EPS 2016 FY Guidance US XTANDI Sales (1) $1,425 - $1,525 Non-GAAP Collaboration Revenue (2) $900 - $970 Non-GAAP Operating Expenses (3) $555 - $600 Non-GAAP R&D Expenses $280 - $300 Non-GAAP SG&A Expenses

  14. Slide 14: Non-GAAP Financial Measures

    Non-GAAP Financial Measures

  15. Slide 15: Reconciliation of GAAP Reported to Non-GAAP (1 of 2)

    Reconciliation of GAAP Reported to Non-GAAP (1 of 2)

  16. Slide 16: Reconciliation of GAAP Reported to Non-GAAP (2 of 2)

    Reconciliation of GAAP Reported to Non-GAAP (2 of 2)

  17. Slide 17: Explanation of Adjustments to Reconciliation Tables

    Explanation of Adjustments to Reconciliation Tables a) Upfront and milestone payments from Astellas: Upfront and milestone payments are excluded from non-GAAP financial measures because they occur at irregular intervals and are not related to Medivation’s long term core business going forward; such

Medivation — Q1 2016 Earnings Presentation on 6ix